Pharmaceutical R&D, manufacturing and distribution involves a "relay race" among many actors at different stages of the process. Contracts are usually negotiated each step of the way, from early research grants to development agreements containing intellectual property licenses, from technology transfer for manufacturing to advanced purchase commitments. These agreements are usually kept confidential, however, with limited publicly-available information and understanding of the public interest provisions that might be feasible in any negotiation. Real-world examples of contractual provisions can help to advance understanding of how to ensure medicines are available, affordable and accessible globally, including from the earliest stages of R&D. Julia Barnes-Weise will present the recently-launched MAPGuide, a new online tool providing a collection of actual and template contractual provisions from agreements between different types of organisations; the Guide covers the subjects of access, intellectual property, liability, risk and benefit sharing. Viviana Galli will provide comments, drawing on her experience advocating for the adoption of access conditions in public funding at different levels within the European Union.
- Julia Barnes-Weise, Executive Director, The Global Health Innovation Alliance Accelerator (GHIAA)
- Viviana Galli, Coordinator, European Alliance for Responsible R&D and Affordable Medicines
- Moderated by Suerie Moon, Co-Director, Global Health Centre